

**PERIPHERAL NEUROPATHY AND AUTONOMIC DYSFUNCTION IN  
HEPATITIS C VIRUS (HCV) RELATED CHRONIC LIVER DISEASE**

*thesis*

**Submitted for Partial Fulfillment of the Master  
Degree in Internal Medicine**

*By*

**Salah Ata Allah Hamada Ahmed**

**(M.B., B.CH.)**

*Supervised by*

**Prof.DR. AFAF ABD EL-ADL EL SAWY**

*Professor of Internal Medicine  
Faculty of Medicine  
Cairo University*

**DR. WAEL MOHAMED AREF**

*Lecturer of Internal Medicine  
Faculty of Medicine  
Cairo University*

**DR. AYAT ALLAH FAROUK AHMED**

*Lecturer of Clinical Neuro Physiology  
Faculty of Medicine  
Cairo University*

*Internal Medicine Department  
Faculty of Medicine  
Cairo University*

**2007**

# ABSTRACT

polyneuropathy occurs with a combination of multiple symptoms, signs, and abnormal electrodiagnostic studies so electrophysiological examination should always be done to avoid underestimating peripheral neuropathy.

Autonomic disturbance can be assessed by recording PASP even in subclinical conditions. Also it gives a quantitative data about the degree of damage of descending sympathetic fibers, so that it will be very helpful for early diagnosis of autonomic dysfunction

## **Key words:**

**HCV - Peripheral – Neuropathy - Autonomic– Neuropathy**

# *Acknowledgement*

First and foremost thanks to Allah, most merciful and greatest beneficent.

I would like to express my deep thanks to **Prof. Dr. Afaf Abd El-adl El Sawy**, Prof. of Internal Medicine, Cairo University, for the great effort and concern she has shown during the proposal and carrying out of this work.

Also I express my gratitude to **Dr. Wael Mohamed Aref** Lecturer of Internal Medicine, Cairo University for his encouragement and valuable advise that guided me throughout this thesis.

I carry a deep gratitude to **Dr. Ayat Allah Farouk Ahmed** Lecturer of Clinical NeuroPhysiology, Cairo University, for her supervision, continuous guidance and objective help.

I would like to express my deep thanks to **Prof. Dr. Nadia Kamal Marie**, Prof. of Internal Medicine. Al. Azhar University and Dr. **Rokaya Abdel. Aziz Mohamed** Assist. Prof of Internal Medicine, Cairo University, whom coming to discusse my study.

# CONTENTS

<b><i>Introduction and aim of the work</i></b>	1-3
<b><i>Review of literature</i></b>	4-97
* Hepatitis C. Virus	4
* Epidemiology Of hepaitis C virus	7
* The Infection	12
* Diseases associated with HCV	21
* Risk factors for liver fibrosis progression in patients with chronic hepatitis C	30
* Extra-hepatic manifestations of hepatitis C infection	35
* Diagnosis of HCV infection	47
* Prevention and control of HCV	55
* Antiviral chemotherapy for hepatitis C	57
* Peripheral neuropathy	75
* Autonomic neuropathy	78
* Evaluation of the autonomic nervous system	83
* Peripheral neuropathy and autonomic dysfunction in hepatitis C virus	87
<b><i>Subjects and methods</i></b>	100
<b><i>Results</i></b>	106
<b><i>Discussion</i></b>	120
<b><i>Summary, Conclusion</i></b>	125-127
<b><i>Recommendation</i></b>	128
<b><i>References</i></b>	129
<b><i>Arabic summary</i></b>	1

## List of Tables

<b>Table</b>	<b>Table title</b>	<b>Page No.</b>
<b><u>Table 1</u></b>	<b>Isolates previously classified types 7,8,9 or 10 and 11 have been reclassified within type 3 and type 6 respectively</b>	<b>6</b>
<b><u>Table 2</u></b>	<b>Extrahepatic manifestation of HCV infection</b>	<b>37</b>
<b><u>Table 3</u></b>	<b>Mean <math>\pm</math> SD of age among examined groups</b>	<b>106</b>
<b><u>Table 4</u></b>	<b>Sex distribution among examined groups</b>	<b>107</b>
<b><u>Table 5</u></b>	<b>Clinical data of peripheral and autonomic neuropathy in different groups and the significance of difference between groups</b>	<b>107</b>
<b><u>Table 6</u></b>	<b>Mean <math>\pm</math> SD of the amplitude and latency of sensory nerve response in the ulnar and medial plantar nerves in the different groups of the study and the significance of difference between the groups</b>	<b>108</b>
<b><u>Table 7</u></b>	<b>Mean <math>\pm</math> SD of the amplitude and latency of sympathetic skin response (SSR) in the upper and lower limbs in the different groups of the study and the significance of difference between the groups</b>	<b>110</b>
<b><u>Table 8</u></b>	<b>Difference between the 3 groups as regards the significant neurophysiological parameters</b>	<b>112</b>
<b><u>Table 9</u></b>	<b>Percentage of abnormalities among different neurophysiological parameters</b>	<b>113</b>
<b><u>Table 10</u></b>	<b>Percentage of tingling within sensory, sympathetic and polyneuropathy tests</b>	<b>115</b>
<b><u>Table 11</u></b>	<b>Percentage of hypothesia within sensory, sympathetic and polyneuropathy tests</b>	<b>116</b>
<b><u>Table 12</u></b>	<b>Percentage of trophic within sensory, sympathetic and polyneuropathy tests</b>	<b>117</b>
<b><u>Table 13</u></b>	<b>Percentage of impotence within sensory, sympathetic and polyneuropathy tests</b>	<b>118</b>
<b><u>Table 14</u></b>	<b>Percentage of orthostatic BP within sensory, sympathetic and polyneuropathy tests</b>	<b>119</b>

## List of Figures

<b>Fig. No.</b>	<b>Figure title</b>	<b>Page No.</b>
<b><u>Fig. 1</u></b>	<b>Clinical outcomes of HCV infection</b>	<b>22</b>
<b><u>Fig. 2</u></b>	<b>Mean medial planter N. sensory CV (M/sec) in the three studied groups.</b>	<b>109</b>
<b><u>Fig. 3</u></b>	<b>Mean medial planter N. sensory amplitude (uv) in the three studied groups.</b>	<b>109</b>
<b><u>Fig. 4</u></b>	<b>Mean SSR amplitude (uv) in UL in the three studied groups.</b>	<b>111</b>
<b><u>Fig. 5</u></b>	<b>Polyneuropathy sensory and/or autonomic among cirrhotic and ch. active hepatitis patients</b>	<b>114</b>

## List Of Abbreviations

<b>ALT</b>	<b>Alanine aminotransferase</b>
<b>AN</b>	<b>Autonomic neuropathy</b>
<b>ANA</b>	<b>Antinuclear antibody</b>
<b>Anti. HBs</b>	<b>Anti hepatitis B surface antigen</b>
<b>CNS</b>	<b>Central nervous system</b>
<b>C1</b>	<b>Complement Component 1</b>
<b>C3</b>	<b>Complement Component 3</b>
<b>C4</b>	<b>Complement Component 4</b>
<b>CHC</b>	<b>Chronic hepatitis virusC</b>
<b>Cox-2</b>	<b>Cyclo oxygenase 2</b>
<b>CTL</b>	<b>Cytotoxic T lymphocyte</b>
<b>DM</b>	<b>Diabetes mellitus</b>
<b>DNA</b>	<b>Deoxy ribonuclease</b>
<b>ECG</b>	<b>Electro cardiogram</b>
<b>EIA</b>	<b>Enzyme immuno assay</b>
<b>ELISA</b>	<b>Enzyme linked immune sorbant assay</b>
<b>EMC</b>	<b>Essential mixed cryoglobulinaemia</b>
<b>EVR</b>	<b>Early virologic response</b>
<b>GBS</b>	<b>Guillain-Barre Syndrome</b>
<b>GIT</b>	<b>Gastro intestinal tract</b>
<b>HBV</b>	<b>Hepatitis B virus</b>
<b>HCC</b>	<b>Hepato cellular carcinoma</b>
<b>HCV</b>	<b>Hepatitis C virus</b>
<b>HIV</b>	<b>Human immune deficiency virus</b>
<b>HSV</b>	<b>Herpes simplex virus</b>
<b>IFN</b>	<b>Interferon</b>

<b>IgG</b>	<b>Immunoglobulin G</b>
<b>IgM</b>	<b>Immunoglobulin M</b>
<b>IL</b>	<b>Interleukin</b>
<b>ITP</b>	<b>Immune thrombocytopenic purupra</b>
<b>LKM</b>	<b>Liver Kidney microsomal antibody</b>
<b>LP</b>	<b>Lichen planus</b>
<b>M. Nos</b>	<b>Macrophage nitric oxide synthase</b>
<b>MHC</b>	<b>Major histocompatiblity</b>
<b>MMP</b>	<b>Matrix metallo proteinases</b>
<b>NF</b>	<b>Nuclear factor</b>
<b>NHL</b>	<b>Non-Hodgkin's lymphoma</b>
<b>No</b>	<b>Nitric oxide</b>
<b>ORF</b>	<b>Open reading fram</b>
<b>PCR</b>	<b>Polymerase chain reaction</b>
<b>PEG IFN</b>	<b>Pegylated interferon</b>
<b>PN</b>	<b>Peripheral neuropathy</b>
<b>RA</b>	<b>Rheumatoid arthritis</b>
<b>RIBA</b>	<b>Recombinant immunoblot assay</b>
<b>RNA</b>	<b>Ribonucleic acid</b>
<b>RT-PCR</b>	<b>Reverse-transcriptase polymerase chain reaction</b>
<b>S.S</b>	<b>Sjogren's syndrome</b>
<b>SLE</b>	<b>Systemic lupus erythramatous</b>
<b>SMA</b>	<b>Smooth muscle antibody</b>
<b>SSR</b>	<b>Sympathetic skin response</b>
<b>SVR</b>	<b>Sustained virologic response</b>
<b>TNF</b>	<b>Tumour necrosis factor</b>
<b>Vs</b>	<b>Versus</b>
<b>γ. GT</b>	<b>Gamma Glutamyle Transferase</b>





# **Introduction and Aim of the Work**

## INTRODUCTION

Hepatitis C virus (HCV) infection affects approximately 170 million persons world wide and is a pandemic 5 times larger than that of HIV. In united states and Brazil, approximately 2% of the population is seropositive for HCV. In Egypt, 28% of the population is seropositive for HCV (*Frank et al., 2000*).

The most common mode of HCV transmission is percutaneous exposure to contaminated blood, including situations associated with intravenous drug use and blood transfusions. HCV infection is a common cause of chronic liver disease, cirrhosis and hepatocellular carcinoma (*Lauer et al., 2001*).

In addition to the liver manifestations, chronic HCV infection may be associated with a series of extra hepatic manifestations, such as mixed cryoglobulinaemia, membranoproliferative glomerulonephritis, auto immune thyroiditis and lymphoproliferative disorders.

These manifestations result from lymphoproliferative and/or auto immune mechanisms, and occur in 40 to 75% of patients with chronic HCV infection (*Gordon, 1996*).

The association of HCV infection with mixed cryoglobulinemia and peripheral neuropathy has been previously reported (*Zaltron et al., 1998*).

However, its pathogenesis is not completely understood, nor do formal treatment guidelines exist. Peripheral neuropathy and detectable serum cryoglobulins appear in approximately one third of patients with HCV infection, but HCV-infected patients with peripheral neuropathy in the absence of serum cryoglobulins have also been described (*Zaltron et al., 1998 and lidove et al., 2001*).

Cardiovascular autonomic and peripheral sensory neuropathy is a known complication of chronic liver disease (*Szalay et al., 1998*).

Cardiovascular autonomic neuropathy (AN) represents a serious complication as it carries a 5-fold risk of mortality in patients with chronic liver disease (*Hendrickse et al., 1992*).

Autonomic neuropathy may also be regarded as a potential etiologic factor of hyperdynamic circulation and portal hypertension (*Kempler et al., 1996*).

## **AIM OF THE WORK**

Due to the importance and prevalence of HCV in Egypt, this study will be carried out to delineate the spectrum of HCV associated neuropathy and assess its relation to liver cirrhosis.



# Review of literature

## **Review of Literature**

### **Hepatitis C. Virus**

HCV is a small RNA virus of about 9400 nucleotide bases (*Choo et al., 1989*).

Details of the ultrastructure of hepatitis C virus virion remain unclear because it has proved extremely difficult to visualize virus particles from infected serum and tissues directly. Although much is known about the viral genome, first cloned in 1989, little is known about HCV morphogenesis, due to the lack of efficient in vitro culture system. Virus- like particles, obtained by expressing genes encoding the HCV structural proteins in mammalian cell, can be used as an alternative model for studying HCV morphogenesis. (*Roingeard et al., 2004*)

Humans are the only host species found to be naturally infected by HCV.

The only animals that are consistently susceptible to experimental HCV infection are chimpanzees, which develop a persistent viraemia and signs of hepatitis. (*Bassett et al., 1998*)

Also the cloning of viral genome was achieved from pooled chimpanzees plasma. (*Choo, et al., 1989*)

Clinical and experimental data indicate the marked hepatotropism of HCV. Thus, in vivo, hepatocytes are currently believed to represent the major targets of virus replication. (*Cho et al., 1996*)

Numerous attempts to grow HCV in vitro have been done, but to date, success has been modest. By using the reverse-transcriptase polymerase chain reaction (RT- PCR), evidence of low-grade viral replication has been obtained in primary human and chimpanzee liver cells. (*Ito et al., 1996*)

In general, the virus titres produced have not only been low, but have also fluctuated markedly, with a tendency of the virus to disappear within days or weeks. (*Shimizu et al., 1994*).

Further efforts are clearly needed to establish efficient means for reliable in vitro culture of HCV. (*Morrica et al., 1999*).

### **The Genome and The Proteins Encoded:**

HCV is a positive RNA virus with a genome which is a single stranded containing approximately 9500 nucleotides. It has an open reading frame (ORF) that encodes a large polyprotein of about 3000 aminoacids and is characterized by extensive genetic diversity (*Lyra et al., 2004*).

The HCV- encoded polyprotein is cleaved post-translationally into multiple structural and non-structural peptides (*Lauer et al., 2001*).

### **Classifications and nomenclature of HCV genotypes:**

HCV has been classified into at least 6 major genotypes with many subtypes and circulate within an infected individual as a number of closely related but distinct variants known as quasispecies (*Lyra et al., 2004*).

These genotypes differ by as much as 31 to 34 percent in their nucleotide sequences, whereas subtypes differ by 20 to 23 percent based on full-length genomic sequence comparisons (*National Institute of Health, (NIH), 2002*).